The present disclosure relates to a combination of the anti-IL-23 antibody tildrakizumab in combination with a corticosteroid for use in the treatment of plaque psoriasis.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (Inde)
SUN PHARMACEUTICAL INDUSTRIES LIMITED (Inde)
Inventeur(s)
Chidrewar, Gajanan
Mandhane, Sanjay
Ramanathan, Vikram Krishna
Abrégé
The disclosure relates to methods of treating autoimmune disorders or reducing or suppressing the symptoms of a chronic inflammatory disorder of the digestive tract using an inhibitor of the interleukin-23 signaling pathway and a modulator of the sphingosine-1- phosphate signaling pathway. The disclosure also relates to pharmaceutical compositions comprising an inhibitor of the interleukin-23 pathway and a modulator of the sphingosine-1- phosphate signaling pathway. The disclosure further relates to combinations of an inhibitor of the interleukin-23 signaling pathway and a modulator of the sphingosine-1-phosphate signaling pathway for use in the treatment of autoimmune disorders. The disclosure further relates to pharmaceutical kits comprising an inhibitor of the interleukin-23 signaling pathway, a modulator of the sphingosine-1-phosphate signaling pathway, and instructions for use. The disclosure further relates to the use of a combination of an inhibitor of the interleukin-23 signaling pathway and a modulator of the sphingosine-1-phosphate signaling pathway for the manufacture of a medicament for treating an autoimmune disorder.
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to an aqueous composition of cholecalciferol. The present invention relates to an oil-free, stable, aqueous composition of cholecalciferol at a concentration ranging from 400 IU-600000 IU. The invention also includes process of preparing such compositions and use of such compositions for the treatment and prevention of vitamin D deficiency.
36 - Services financiers, assurances et affaires immobilières
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Manuals; newsletters; pamphlets and brochures; pharmaceutical information leaflets; quick reference pocket guides (1) Administration of prescription drug programs designed to process medical insurance claims for products used by consumers; business administration of a patient support program for facilitating access to pharmaceutical products; business administration of a patient support program for facilitating the distribution of pharmaceutical products; business administration of a patient support program for facilitating the reimbursement of pharmaceutical product; consulting services in the field of patient relationship management for healthcare providers; patient relationship management services
(2) Charitable services, namely, providing financial support to disadvantaged patients for the purpose of facilitating good health; providing financial support to patients for the purchase of medications
(3) Advisory and consultancy services for patients in the field of patient access to medical treatment services; charitable services, namely, patient assistance program to provide drugs free of charge to low-income patients without prescription drug coverage; information, advisory and consultancy services in the field of medical testing services; medical nursing services; providing information relating to the preparation and dispensing of medications
36 - Services financiers, assurances et affaires immobilières
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Manuals; newsletters; pamphlets and brochures; pharmaceutical information leaflets; quick reference pocket guides (1) Administration of prescription drug programs designed to process medical insurance claims for products used by consumers; business administration of a patient support program for facilitating access to pharmaceutical products; business administration of a patient support program for facilitating the distribution of pharmaceutical products; business administration of a patient support program for facilitating the reimbursement of pharmaceutical product; consulting services in the field of patient relationship management for healthcare providers; patient relationship management services
(2) Charitable services, namely, providing financial support to disadvantaged patients for the purpose of facilitating good health; providing financial support to patients for the purchase of medications
(3) Advisory and consultancy services for patients in the field of patient access to medical treatment services; charitable services, namely, patient assistance program to provide drugs free of charge to low-income patients without prescription drug coverage; information, advisory and consultancy services in the field of medical testing services; medical nursing services; providing information relating to the preparation and dispensing of medications
7.
PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
The present invention relates to tirzepatide or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof. The present invention also relates to novel fragments as intermediates and use thereof in the preparation of tirzepatide.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
8.
CYCLOSPORINE FORMULATIONS FOR USE IN PATIENTS UNDERGOING CATARACT SURGERY
A method of preparing patients for cataract surgery includes topical administration of a cyclosporine solution. The administration may occur twice daily and may occur over the course of 28 days. The method results in an improved error prediction for 1-month spherical equivalent refractive outcome and improved ocular surface irregularity.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Providing online information regarding patient experiences with plaque psoriasis treatments, namely, featuring supportive personal stories on the subjects of health, emotional impact of plaque psoriasis, and treatment
The present invention relates to long acting glucagon-like peptide-1 and human glucose- dependent insulinotropic polypeptide (GIP) agonist polypeptides which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
The disclosure relates to methods of using GLP-1 analog and composition thereof for the treatment of metabolic disorders, such as obesity, diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and hypertriglyceridemia. More specifically, the disclosure relates to methods for treating obesity in a subject, comprising administering a therapeutically effective amount of GL0034 to the subject. The disclosure also relates to methods for treating a metabolic disorder in a subject in need thereof, comprising administering a therapeutically effective amount of GL0034 to the subject. The disclosure further relates to compositions comprising GL0034 for the treatment of obesity, diabetes or other metabolic disorder in a subject.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 3/08 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A stable nanomicellar ophthalmic solution comprising cyclosporine and a method of preparing the nanomicellar solution. The present invention further relates to a stable nanomicellar solution comprising a cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 or amorphous cyclosporine. The present invention also relates to use of this stable nanomicellar ophthalmic solution in the treatment of dry eye.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
13.
METHOD OF INJECTING DIHYDROERGOTAMINE INTO THE BODY
A method is provided for the acute treatment of migraine headaches with or without aura by injecting dihydroergotamine mesylate into a subject. The method includes storing the dihydroergotamine mesylate in an autoinjector at room temperature in a foil pouch. The method further includes removing the autoinjector from the pouch; removing a cap of the autoinjector; pushing the autoinjector down against an injection site of the subject to depress a safety guard; pressing and releasing an activation button on the autoinjector to start injection; and holding the autoinjector against the injection site for at least 10 seconds irrespective of whether a click is generated. The method further includes confirming that the injection is complete by viewing a change of color in a viewing window of the autoinjector, and lifting the autoinjector up away from the injection site and allowing the guard to drop down and lock over a needle.
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
14.
GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS
The present invention relates to GLP-1/GIP/GCG triple receptor agonists and use thereof in the treatment or prevention of Type 2 diabetes mellitus (T2DM), hyperlipidemia/dyslipidemia, metabolic syndromes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risks, and/or obesity.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 38/00 - Préparations médicinales contenant des peptides
A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
16.
GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS
The present disclosure provides GLP-1/GIP and GLP-1/GCG dual receptor agonists comprising incretin analog polypeptides and use thereof in the treatment or prevention of Type 2 diabetes mellitus (T2DM), hyperlipidemia/dyslipidemia, metabolic syndromes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction- associated steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risks, and/or obesity.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 38/00 - Préparations médicinales contenant des peptides
The present invention relates to long acting glucagon-like peptide-1 and human glucose-dependent insulinotropic polypeptide (GIP) dual agonist polypeptide which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.
G06N 3/0985 - Optimisation d’hyperparamètresMeta-apprentissageApprendre à apprendre
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
18.
STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF
The present invention relates to a stable nanomicellar ophthalmic formulation comprising cyclosporine, hydrogenated 40 polyoxyl castor oil, octoxynol-40, and an aqueous vehicle, wherein the stable nanomicellar ophthalmic formulation is made by a method comprising: a) mixing the hydrogenated 40 polyoxyl castor oil and the octoxynol-40, wherein the mixing produces a Mixture A comprising a water content of less than 3%; b) adding the cyclosporine to the Mixture A to form a Mixture B; and c) mixing the Mixture B with the aqueous vehicle, thereby forming the stable nanomicellar ophthalmic formulation.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
19.
METHODS AND COMPOSITIONS FOR TREATING PLAQUE PSORIASIS
This disclosure relates to methods of treating plaque psoriasis comprising administering an anti-IL-23p19 antibody hum13B8-b to a patient in need thereof. This disclosure also relates to pharmaceutical compositions of an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof for the treatment plaque psoriasis in a patient. This disclosure further relates to the use of an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof for the manufacture of a medicament for treating plaque psoriasis in a patient. In some embodiments, the disclosure relates to methods, pharmaceutical compositions, and medicaments for treating plaque psoriasis wherein treatment results in the patient maintaining a Physician's Global Assessment (PGA) score of "clear" or "almost clear" with at least a 2- point reduction from Baseline, or results in the patient maintaining at least a 50% reduction in the Psoriasis Area and Severity Index (PASI 50), or results in the patient maintaining at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75), or results in the patient maintaining at least a 90% reduction in the Psoriasis Area and Severity Index (PASI 90), or results in the patient maintaining a 100% reduction in the Psoriasis Area and Severity Index (PASI 100) for at least up to about 60 weeks to at least up to about 432 weeks. In some embodiments, the disclosure relates to methods, pharmaceutical compositions, and medicaments for treating plaque psoriasis wherein treatment results in the patient experiencing no increase in adverse events (AEs), drug-related AEs, severe adverse events (SAEs), Tier 1 AEs, or Tier 2 AEs for at least up to about 60 weeks to at least up to about 432 weeks.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
This disclosure relates to methods of treating plaque psoriasis comprising administering an anti-IL-23p19 antibody hum13B8-b to a patient in need thereof. This disclosure also relates to pharmaceutical compositions of an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof for the treatment plaque psoriasis in a patient. This disclosure further relates to the use of an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof for the manufacture of a medicament for treating plaque psoriasis in a patient. In some embodiments, the disclosure relates to methods, pharmaceutical compositions, and medicaments for treating plaque psoriasis wherein treatment results in the patient maintaining a Physician's Global Assessment (PGA) score of “clear” or “almost clear” with at least a 2-point reduction from Baseline, or results in the patient maintaining at least a 50% reduction in the Psoriasis Area and Severity Index (PASI 50), or results in the patient maintaining at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75), or results in the patient maintaining at least a 90% reduction in the Psoriasis Area and Severity Index (PASI 90), or results in the patient maintaining a 100% reduction in the Psoriasis Area and Severity Index (PASI 100) for at least up to about 60 weeks to at least up to about 432 weeks. In some embodiments, the disclosure relates to methods, pharmaceutical compositions, and medicaments for treating plaque psoriasis wherein treatment results in the patient experiencing no increase in adverse events (AEs), drug-related AEs, severe adverse events (SAEs), Tier 1 AEs, or Tier 2 AEs for at least up to about 60 weeks to at least up to about 432 weeks.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders and immunologically mediated inflammatory disorders; Pharmaceutical preparations for the treatment of cancer
The present invention relates to a method of treating acne comprising administering to the subject, a pharmaceutical composition comprising micronized isotretinoin; wherein, the composition is administered once daily to the subject under a fasting state, at a dose of about 0.4 mg/kg to about 1.6 mg/kg of isotretinoin. In particular, the composition further comprises one or more surfactants; and one or more co-solvents.
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1)(7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A stable nanomicellar ophthalmic solution comprising cyclosporine and a method of preparing the nanomicellar solution. The present invention further relates to the stable nanomicellar solution comprising cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 or amorphous cyclosporine. The present invention also relates to use of this stable nanomicellar L ophthalmic solution in dry eye.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present disclosure relates to a stable pharmaceutical composition comprising a Histamine H2-receptor antagonist or a pharmaceutically acceptable salt thereof and a stabilizing amount of at least one alkalizer. The composition provides effective control of the level of nitrosamine drug substance-related impurities (NDSRIs) such as NDMA in the drug product during shelf life of the product.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations and substances for use in the treatment of diseases and disorders of the central nervous system; pharmaceutical preparations for the treatment of mental disorders
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations and substances for use in the treatment of diseases and disorders of the central nervous system; pharmaceutical preparations for the treatment of mental disorders
The invention relates to stable compositions of an antibody against human programmed death receptor PD-1, or antigen binding fragments thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. The present invention relates to pharmaceutical compositions of an anti-PD1 antibody comprising a buffer, a sugar or sugar alcohol and a surfactant. In some embodiments of the invention, the formulations may be administered to a subject by intravenous or subcutaneous administration.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the prevention of breast cancer in post-menopausal women; Pharmaceutical preparations for the prevention of bone and skeletal diseases
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Providing online information regarding patient experiences with plaque psoriasis treatments, namely, featuring supportive personal stories on the subjects of health, emotional impact of plaque psoriasis, and treatment
45.
TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF
Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
The present disclosure relates to a stable multiparticulate composition comprising coated discrete units of an amine drug or a pharmaceutically acceptable salt thereof, with stabilizing amount of one or more nitrite quencher. The composition provides effective control of the level of nitrosamine drug substance-related impurities (NDSRIs) in the drug product during shelf life of the product.
The present invention relates to an intravenous infusion dosage form comprising: an aqueous solution of pemetrexed or its pharmaceutically acceptable salt at a concentration ranging from 1.0 mg/ml to 20.0 mg/ml present in a multilayered flexible plastic infusion container, wherein the multilayered flexible plastic infusion container has an oxygen scavenger layer sandwiched between an outermost and an innermost layer of the container, the container being free of a polyimide and wherein the multilayered flexible plastic infusion container filled with the aqueous solution of pemetrexed is autoclavable.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
B32B 27/08 - Produits stratifiés composés essentiellement de résine synthétique comme seul composant ou composant principal d'une couche adjacente à une autre couche d'une substance spécifique d'une résine synthétique d'une sorte différente
B32B 27/30 - Produits stratifiés composés essentiellement de résine synthétique comprenant une résine vinyliqueProduits stratifiés composés essentiellement de résine synthétique comprenant une résine acrylique
B32B 27/32 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyoléfines
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the prevention of breast cancer in post-menopausal women; Pharmaceutical preparations for the prevention of bone and skeletal diseases
The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.
39 - Services de transport, emballage et entreposage; organisation de voyages
Produits et services
Retail pharmacy services; mail order pharmacy services; pharmaceutical services, namely, processing telephone prescription orders in retail and central fill pharmacies Distribution services, namely, delivery of pharmaceutical products
39 - Services de transport, emballage et entreposage; organisation de voyages
Produits et services
Retail pharmacy services; mail order pharmacy services; pharmaceutical services, namely, processing telephone prescription orders in retail and central fill pharmacies Distribution services, namely, delivery of pharmaceutical products
The present invention relates to a method of treating blepharitis comprising administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient comprises a glucocorticoid in an ophthalmically acceptable vehicle, such as DuraSite® 2. Additionally, the present invention discloses a kit that includes: (a) a composition comprising about 0.1% by weight dexamethasone in an ophthalmically acceptable vehicle and, optionally, (b) instructions for using the composition for the treatment of blepharitis.
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61F 9/00 - Procédés ou dispositifs pour le traitement des yeuxDispositifs pour mettre en place des verres de contactDispositifs pour corriger le strabismeAppareils pour guider les aveuglesDispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
G06N 3/0985 - Optimisation d’hyperparamètresMeta-apprentissageApprendre à apprendre
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
A parenteral dosage form of diltiazem, comprising a ready-to-infuse, stable aqueous solution comprising diltiazem or its pharmaceutically acceptable salt, a pharmaceutically acceptable stabilizer selected from cyclic oligosaccharides, and an infusion container fdled with the said aqueous solution.
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. clothiapine, diltiazem
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.
A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the prevention of breast cancer in post-menopausal women; Pharmaceutical preparations for the treatment and prevention of bone/skeletal diseases
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the prevention of breast cancer in post-menopausal women; Pharmaceutical preparations for the treatment and prevention of bone/skeletal diseases
62.
METHODS FOR TREATMENT OF SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP
The disclosure relates to an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof and its use in the treatment of plaque psoriasis of the scalp.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
The present invention discloses an extended release multi-particulate sprinkle composition comprising a plurality of discrete units, each discrete unit comprising quetiapine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. clothiapine, diltiazem
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Eye drops; Ocular pharmaceuticals; Pharmaceutical preparations for the treatment and prevention of diseases or disorders of the eye; Pharmaceutical preparations for the treatment of inflammation and pain in the eye
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Cardiovascular drugs for use for the prevention of stroke;
cardiovascular drugs for use in the treatment of congestive
heart failure; cardiovascular drugs for use in angina
pectoris; cardiovascular drugs for the treatment of
arrhythmias; cardiovascular drugs for use in myocardial
infarction.
68.
Method of Injecting Dihydroergotamine Into The Body
A method is provided for the acute treatment of migraine headaches with or without aura by injecting dihydroergotamine mesylate into a subject. The method includes storing the dihydroergotamine mesylate in an autoinjector at room temperature in a foil pouch. The method further includes removing the autoinjector from the pouch; removing a cap of the autoinjector; pushing the autoinjector down against an injection site of the subject to depress a safety guard; pressing and releasing an activation button on the autoinjector to start injection; and holding the autoinjector against the injection site for at least 10 seconds irrespective of whether a click is generated. The method further includes confirming that the injection is complete by viewing a change of color in a viewing window of the autoinjector, and lifting the autoinjector up away from the injection site and allowing the guard to drop down and lock over a needle.
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
69.
METHODS FOR TREATMENT OF SUBJECTS WITH PLAQUE PSORIASIS OF THE SCALP
The disclosure relates to an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof and its use in the treatment of plaque psoriasis of the scalp.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
The present invention relates to long acting glucagon-like peptide-1 and human glucose-dependent insulinotropic polypeptide (GIP) agonist polypeptides which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
The present disclosure relates to a combination of the anti-IL-23 antibody tildrakizumab in combination with a corticosteroid for use in the treatment of plaque psoriasis.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
The present invention relates to extended release liquid compositions of guaifenesin. The extended release liquid compositions are in the form of suspensions which are ready-to-use or suspensions which are reconstituted from powder. It also relates to processes for the preparation of said extended release liquid compositions.
The present invention relates to tirzepatide or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof. The present invention also relates to novel fragments as intermediates and use thereof in the preparation of tirzepatide.
A61K 38/00 - Préparations médicinales contenant des peptides
C07C 233/47 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes carboxyle avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone acyclique ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné acyclique saturé
C07K 1/04 - Procédés généraux de préparation de peptides sur des supports
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A perfusion container for directly administering to patients a dose of an antineoplastic drug calculated according to a patient's parameter, wherein the first perfusion container comprises a solution of antineoplastic drug at a concentration and volume such that the amount of antineoplastic drug in the container is equal to the calculated dose for one patient but less than the calculated dose for a second patient, the calculated dose is provided to first patient within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container, further the first perfusion container is accompanied by a second top-up perfusion container comprising a solution of antineoplastic drug at a concentration and volume such that the calculated dose is provided within 5% variance by directly administering the full volume of the solution of antineoplastic drug from the first perfusion container and the second top-up container to the second patient.
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
76.
METHOD OF INJECTING DIHYDROERGOTAMINE INTO THE BODY
A method is provided for the acute treatment of migraine headaches with or without aura by injecting dihydroergotamine mesylate into a subject. The method includes storing the dihydroergotamine mesylate in an autoinjector at room temperature in a foil pouch. The method further includes removing the autoinjector from the pouch; removing a cap of the autoinjector; pushing the autoinjector down against an injection site of the subject to depress a safety guard; pressing and releasing an activation button on the autoinjector to start injection; and holding the autoinjector against the injection site for at least 10 seconds irrespective of whether a click is generated. The method further includes confirming that the injection is complete by viewing a change of color in a viewing window of the autoinjector, and lifting the autoinjector up away from the injection site and allowing the guard to drop down and lock over a needle.
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61K 31/48 - Dérivés de l'ergoline, p. ex. acide lysergique, ergotamine
A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
A parenteral dosage form having an infusion container filled with an aqueous solution in volumes ranging from 40 ml to 500 ml comprising 1 mg/ml to 2 mg/ml of carboplatin, wherein the solution contains known impurity of 1, 1-cyclobutanedicarboxylic acid in an amount of not more than 1.0% by weight of carboplatin and the solution remains physically stable when stored at room temperature.
A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 μg/mL. The method further includes permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter. The injector is configured to provide at least one audible feedback during the rotation. The method further includes operating the actuator to deliver the octreotide acetate from the cartridge through the needle to treat the subject. The injector is provided with multiple surface portions.
The present invention relates to a method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration.
The present invention further relates to a perfusion system comprising different sets of perfusion containers, each container comprising a ready-to-infuse, stable, sterile, aqueous perfusion solution of a drug, wherein the set of perfusion containers alone or in combination provides for direct intravenous administration of a desired dose of the drug to a patient in need thereof, such that the delivered dose is equal to or within ±5% of the calculated dose.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
G16H 20/13 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients delivrés par des distributeurs
B65B 55/04 - Stérilisation des enveloppes d'emballage ou récipients avant ou pendant l'emballage
B65D 81/26 - Adaptations pour empêcher la détérioration ou l'altération du contenuApplications au réceptacle ou au matériau d'emballage d'agents de conservation des aliments, de fongicides, d'insecticides ou de produits repoussant les animaux avec dispositifs pour évacuer ou absorber les fluides, p. ex. s'écoulant du contenuEmploi de produits empêchant la corrosion ou de dessiccateurs
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
G16Z 99/00 - Matière non prévue dans les autres groupes principaux de la présente sous-classe
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A stable nanomicellar ophthalmic solution comprising cyclosporine and a method of preparing the nanomicellar solution. The present invention further relates to a stable nanomicellar solution comprising a cyclosporine form with characteristic XRD peaks at 2-theta (deg.) 6.9, 7.8, 9.4 and 15.9 or amorphous cyclosporine. The present invention also relates to use of this stable nanomicellar ophthalmic solution in the treatment of dry eye.
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multiparticulate composition is sprinkled onto soft foods or liquids for oral administration. Further, the multiparticulate composition is bioequivalent to the marketed extended release tablet. It further relates to a process of preparation of said multiparticulate composition and method of treatment of patients suffering from angina by administering said composition.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of neurologic disorders, disorders of the nervous system, mental illness, major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, chronic musculoskeletal pain
The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
A method of preparing patients for cataract surgery includes topical administration of a cyclosporine solution. The administration may occur twice daily and may occur over the course of 28 days. The method results in an improved error prediction for 1-month spherical equivalent refractive outcome and improved ocular surface irregularity.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations and substances for the treatment of vertigo; Medicinal preparations and substances for the treatment of vertigo; anti-vertigo medicines.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Intestinal disorder medicine for the treatment of ulcerative colitis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of dermatitis, eczema and psoriasis; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Intestinal disorder medicine for the treatment of ulcerative colitis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of dermatitis, eczema and psoriasis; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Ophthalmic drops; ophthalmological preparations; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of eye infections; pharmaceutical preparations for the treatment of ophthalmic conditions; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in ophthalmology
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Intestinal disorder medicine for the treatment of ulcerative colitis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of dermatitis, eczema and psoriasis; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Ophthalmic drops; ophthalmic preparations; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of eye infections; pharmaceutical preparations for the treatment of ophthalmic conditions; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in ophthalmology
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Intestinal disorder medicine for the treatment of ulcerative colitis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of dermatitis, eczema and psoriasis; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for the treatment and prevention of cancer; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for the treatment and prevention of cancer; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders
